Paroxetine—The Antidepressant from Hell? Probably Not, But Caution Required
By Robert M. Nevels, Samuel T. Gontkovsky, Bryman E. Williams
Duloxetine in Military Posttraumatic Stress Disorder
By Gerardo Villarreal, José M. Cañive, Lawrence A. Calais, Gregory Toney, Ashley K. Smith
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
By Clinton Kilts, PhD
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
Can We Distinguish Anxiety From Depression?
By David S. Baldwin, FRCPsych, Dwight L. Evans, MD, Robert M. A. Hirschfeld, MD, and Siegfried Kasper, MD
Unraveling the Diagnostic Clues of Depression and GAD: The Primary Care Challenge
By Johan A. den Boer, MD, Dwight L. Evans, MD, Sing Lee, MD, PhD, and Rafael Salin-Pascual, MD
Depression Treatment: A Lifelong Commitment?
By Martin B. Keller, MD, and Ernst R. Berndt, PhD
Coping With Somatic Comorbidities: Striving for Complete Recovery
By Christer Allgulander, MD, and Siegfried Kasper, MD
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
By Michael E. Thase, MD, and Madhukar Trivedi, MD
Long-Term Treatment Strategies in Anxiety Disorders
By Christer Allgulander, MD, Robert M. A. Hirschfeld, MD, and David J. Nutt, MD, PhD
Long-Term Treatment Strategies in Affective Disorders
By Martin B. Keller, MD